



Head and Neck Tumors

Guest Editor:

Prof. Dr. Jan Plzak

Department of
Otorhinolaryngology, Head and
Neck Surgery, First Faculty of
Medicine, Charles University and
University Hospital Motol,
Prague, Czech Republic

Deadline for manuscript
submissions:

closed (15 March 2022)

Message from the Guest Editor

Special Issue with the title “Head and Neck Tumors” summarizes recent advances and knowledge about not only malignant, but also benign tumors of head and neck regions. During last 5 to 10 years broad spectrum of new findings about head and neck cancers has been published and some of them bring key prognostic and therapeutic improvements for the patients. More complex approach for therapeutic decision for benign tumors in otorhinolaryngology and skull base surgery is applied recently. More precise and reliable prognostic markers are necessary not only for malignant but also for benign diseases.

This special issue is devoted to original basic, translational or clinical research or review articles that focus on pathogenesis mechanisms of diseases, translational medical research, biomaterials, therapy including biologic and immunotherapy, biomarkers, novel insights of the treatment of recurrent and metastatic disease as well as the personalization of treatment based on the molecular characteristics of individual tumors, etc. in head and neck.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)